Compare Hormel Foods Corp (HRL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs TransMedics Group Inc — how do they compare? Hormel Foods Corp trades at $19.19 (market cap $10.69B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Hormel Foods Corp is far larger — about 3.9× TransMedics Group Inc's market cap, and Hormel Foods Corp pays a 6.02% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and TransMedics Group Inc for 24 Days on average.
| HRL | TMDX | |
|---|---|---|
Market Cap | $10.69B | $2.74B |
Volume | 10,041,387 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $150.42 |
52-Week Low | $19.19 | $61.99 |
Typical Hold Time | 99 Days | 24 Days |
Enterprise Value | $12.67B | $3.13B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.42, down 0.66% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, though recent quarters beat EPS estimates. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, while maintaining a 60-year dividend streak. Cash flow trends show improvement from 2025's negative $71M to projected 2026 positive $245M.
HRL presents a value opportunity with 25% upside to consensus target of $24.25, supported by dividend stability. However, declining profit margins and elevated valuation multiples pose headwinds. The Brakebush integration execution and consumer spending trends will be critical for reversing earnings pressure amid competitive food markets.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
